Dollars for degradation

C4 Therapeutics Inc. parlayed strong preclinical data into a tranched $73 million series A round and a deal with Roche (SIX:ROG; OTCQX:RHHBY) that will allow the newco to pursue several indications with its protein degradation platform and bring both its lead programs into Phase I/II testing.

C4's Degronimid technology uses small molecules to tag disease-associated proteins with ubiquitin, which then triggers the proteins' degradation by the proteasome. The company has exclusive, worldwide rights to the technology from Dana-Farber Cancer Institute, along with two targeted protein degradation candidates slated to enter the clinic in 18-24 months. ...